• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    10/30/23 9:05:49 AM ET
    $CDIO
    $COCH
    $EAR
    $LUMO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Industrial Specialties
    Health Care
    Get the next $CDIO alert in real time by email

    Gainers

    • Miromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands at $91.7 million.
    • Eargo (NASDAQ:EAR) stock rose 54.16% to $2.59. The company's market cap stands at $53.7 million.
    • VYNE Therapeutics (NASDAQ:VYNE) shares rose 52.33% to $3.42. The market value of their outstanding shares is at $11.2 million.
    • SELLAS Life Sciences Gr (NASDAQ:SLS) stock increased by 25.05% to $1.17. The market value of their outstanding shares is at $33.1 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares rose 23.19% to $0.51. The market value of their outstanding shares is at $2.9 million.
    • Reviva Pharmaceuticals (NASDAQ:RVPH) stock rose 21.59% to $4.56. The market value of their outstanding shares is at $103.2 million.

    Losers

    • Envoy Medical (NASDAQ:COCH) shares decreased by 14.3% to $1.2 during Monday's pre-market session. The company's market cap stands at $25.2 million.
    • Lumos Pharma (NASDAQ:LUMO) shares decreased by 12.71% to $3.29. The market value of their outstanding shares is at $26.1 million.
    • Revvity (NYSE:RVTY) stock decreased by 12.64% to $85.5. The company's market cap stands at $10.6 billion. The company's, Q3 earnings came out today.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares decreased by 11.25% to $0.7. The company's market cap stands at $2.5 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) stock decreased by 10.59% to $0.76. The company's market cap stands at $3.8 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock declined by 10.23% to $0.21. The market value of their outstanding shares is at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CDIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDIO
    $COCH
    $EAR
    $LUMO

    CompanyDatePrice TargetRatingAnalyst
    Revvity Inc.
    $RVTY
    12/15/2025$110.00Buy → Neutral
    BofA Securities
    Revvity Inc.
    $RVTY
    12/9/2025$105.00Neutral
    Goldman
    Revvity Inc.
    $RVTY
    10/16/2025Neutral
    Guggenheim
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    Revvity Inc.
    $RVTY
    5/1/2025$115.00Neutral → Buy
    UBS
    Revvity Inc.
    $RVTY
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    Revvity Inc.
    $RVTY
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $CDIO
    $COCH
    $EAR
    $LUMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $CDIO
    $COCH
    $EAR
    $LUMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Victor Miriame exercised 1,862 shares at a strike of $95.74 and sold $180,856 worth of shares (1,862 units at $97.13) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/26/26 4:05:03 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Mcmurry-Heath Michelle sold $58,356 worth of shares (600 units at $97.26), decreasing direct ownership by 12% to 4,233 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/25/26 4:05:12 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Victor Miriame covered exercise/tax liability with 1,031 shares, decreasing direct ownership by 5% to 18,122 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/19/26 4:05:13 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CDIO
    $COCH
    $EAR
    $LUMO
    SEC Filings

    View All

    Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    2/27/26 9:11:14 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by VYNE Therapeutics Inc.

    10-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    2/27/26 8:01:39 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Revvity Inc.

    10-K - REVVITY, INC. (0000031791) (Filer)

    2/24/26 4:10:08 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CDIO
    $COCH
    $EAR
    $LUMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity downgraded by BofA Securities with a new price target

    BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00

    12/15/25 9:57:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Revvity with a new price target

    Goldman initiated coverage of Revvity with a rating of Neutral and set a new price target of $105.00

    12/9/25 8:53:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Revvity

    Guggenheim initiated coverage of Revvity with a rating of Neutral

    10/16/25 8:27:52 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CDIO
    $COCH
    $EAR
    $LUMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envoy Medical Regains Compliance with Nasdaq Listing Requirement

    White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b).As previously disclosed, the Company received a notice from Nasdaq on February 25, 2025, indicating that it was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35

    2/24/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space

    White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry."We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical. "As the industry realizes the wisdom and flexibility of our appro

    2/23/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial

    Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization Company hosting Fireside Chat with Dr. Theodore McRackan, on February 25th at 10 a.m. ET, to discuss his initial experiences as clinical trial's leading implanterWhite Bear Lake, Minnesota--(Newsfile Corp. - February 19, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutio

    2/19/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $CDIO
    $COCH
    $EAR
    $LUMO
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

    NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

    7/7/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDIO
    $COCH
    $EAR
    $LUMO
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CDIO
    $COCH
    $EAR
    $LUMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials